Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
EQRx, Inc. - Common Stock
(NQ:
EQRX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about EQRx, Inc. - Common Stock
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
September 27, 2023
From
Robbins LLP
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)
August 10, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
August 02, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders
August 01, 2023
From
Halper Sadeh LLC
Via
Business Wire
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
August 01, 2023
From
Revolution Medicines, Inc.; EQRx, Inc.
Via
GlobeNewswire
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
May 08, 2023
From
EQRx, Inc.
Via
GlobeNewswire
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
April 27, 2023
From
EQRx, Inc.
Via
GlobeNewswire
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
April 21, 2023
From
Robbins LLP
Via
Business Wire
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
February 23, 2023
From
EQRx, Inc.
Via
GlobeNewswire
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
EQRx, Inc.
Via
GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
December 19, 2022
From
EQRx, Inc.
Via
GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
December 02, 2022
From
EQRx, Inc.
Via
GlobeNewswire
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
November 10, 2022
From
EQRx, Inc.
Via
GlobeNewswire
EQRx to Participate in the Jefferies 2022 London Healthcare Conference
November 07, 2022
From
EQRx, Inc.
Via
GlobeNewswire
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
October 28, 2022
From
EQRx, Inc.
Via
GlobeNewswire
EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022
July 28, 2022
From
Eqrx, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.